| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 28% YoY growth in Q1 FY27. |
|---|---|
| Margins | Targeting 15%+ EBITDA margins as capacity utilization improves. |
| Demand visibility | Positive momentum in domestic and international specialty chemicals. |
| Management confidence | Bullish on prospects, especially international markets and new product ramps. |
Growth
Consolidated revenue grew 28% YoY; HPPC, TSC, and AHN segments each grew approximately 28% YoY; Exports up 21%.
Outlook
Management targets 15% top-line growth for FY27 and aims for 15%+ steady-state EBITDA margins through B2C rationalization.
Risks
EBITDA margins compressed to 11.6% from 12.5% due to raw material volatility, freight costs, and B2C segment losses.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 28% (= BEAT)
- Guided 12-13% EBITDA margin → delivered 11.6% (= PARTIAL)
- Guided Thailand plant operational Q2 → delivered operational (= BEAT)
Partly delivered
- Guided debt reduction/debt-free 18mo → delivered net debt Rs. 248 Cr (= PARTIAL)
Missed
- Guided B2C/Institutional breakeven FY27 → delivered losses (= MISS)
Investor Presentation filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹423.20
- Market cap
- ₹2,344 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.6×Sector 37.2×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Other Announcement
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Management Change
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Annual General Meeting
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech Results Update
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.
Rossari Biotech Merger & Restructuring Worth ₹24 Cr
Rossari Biotech is selling its wholly-owned subsidiary, Rossari International Limited Company, to its Singapore subsidiary for approximately ₹24 Crore. This internal restructuring completes by March 2027.
- Value
- ₹24.00 Cr